INVA - Innoviva, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.67
+0.20 (+1.03%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close19.47
Open19.54
Bid19.45 x 1100
Ask20.00 x 2900
Day's Range19.48 - 19.81
52 Week Range13.26 - 19.82
Volume663,244
Avg. Volume1,134,435
Market Cap1.987B
Beta (3Y Monthly)0.84
PE Ratio (TTM)11.56
EPS (TTM)1.70
Earnings DateFeb 6, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2015-09-08
1y Target Est15.50
Trade prices are not sourced from all markets
  • Markit5 days ago

    See what the IHS Markit Score report has to say about Innoviva Inc.

    # Innoviva Inc ### NASDAQ/NGS:INVA View full report here! ## Summary * Bearish sentiment is moderate ## Bearish sentiment Short interest | Neutral Short interest is moderate for INVA with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $3.77 billion over the last one-month into ETFs that hold INVA are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Dow Jones Gives Back Little Of Its 1,100-Point Rebound; 3 Signs Stock Market Bears Are Retreating
    Investor's Business Daily9 days ago

    Dow Jones Gives Back Little Of Its 1,100-Point Rebound; 3 Signs Stock Market Bears Are Retreating

    The Dow Jones industrial average and other key averages still show strength in 2019 after the big slide in Q4 last year. Market technicals are improving.

  • Markit11 days ago

    See what the IHS Markit Score report has to say about Innoviva Inc.

    # Innoviva Inc ### NASDAQ/NGS:INVA View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate ## Bearish sentiment Short interest | Neutral Short interest is moderate for INVA with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding INVA is favorable, with net inflows of $6.63 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 3 Under-the-Radar Value Stocks to Buy in 2019
    Motley Fool19 days ago

    3 Under-the-Radar Value Stocks to Buy in 2019

    These might be the cheapest stocks you've never heard about.

  • Is Innoviva (INVA) Stock Outpacing Its Medical Peers This Year?
    Zackslast month

    Is Innoviva (INVA) Stock Outpacing Its Medical Peers This Year?

    Is (INVA) Outperforming Other Medical Stocks This Year?

  • See what the IHS Markit Score report has to say about Innoviva Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Innoviva Inc.

    Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • IBD 50 Stocks To Watch: Innoviva Resilient As Broad Market Struggles
    Investor's Business Dailylast month

    IBD 50 Stocks To Watch: Innoviva Resilient As Broad Market Struggles

    Innoviva is among a select group of stocks to watch in the biotech sector thanks to strong fundamentals and a bullish chart.

  • Hedge Funds Aren’t Crazy About Innoviva, Inc. (INVA) Anymore
    Insider Monkeylast month

    Hedge Funds Aren’t Crazy About Innoviva, Inc. (INVA) Anymore

    As we already know from media reports and hedge fund investor letters, many hedge funds lost money in October, blaming macroeconomic conditions and unpredictable events that hit several sectors, with healthcare among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent declines. […]

  • 3 Reasons Momentum Stock Investors Will Love Innoviva (INVA)
    Zackslast month

    3 Reasons Momentum Stock Investors Will Love Innoviva (INVA)

    Innoviva (INVA) stock is looking quite impressive for momentum-oriented investors as it has favorable price performance and is also seeing positive estimate revisions.

  • Stocks Trim Losses As Consumer Stocks Rise At Start Of Holiday Shopping Season
    Investor's Business Daily2 months ago

    Stocks Trim Losses As Consumer Stocks Rise At Start Of Holiday Shopping Season

    Stocks pared losses as the market started the final hour of a shortened session Friday, while some consumer stocks led at the start of the holiday shopping season.

  • See what the IHS Markit Score report has to say about Innoviva Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Innoviva Inc.

    Short interest is moderate for INVA with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold INVA had net inflows of $3.42 billion over the last one-month.

  • IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses
    Investor's Business Daily2 months ago

    IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses

    Innoviva is the IBD Stock Of The Day as the biotech stock flirts with a breakout amid new uses for its GlaxoSmithKline-partnered medicines. Innoviva has several royalty deals with Glaxo.

  • Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe
    Zacks2 months ago

    Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe

    Glaxo (GSK) and Innoviva announce approval of label expansion for COPD drug, Trelegy Ellipta, in Europe to include patients not adequately treated with dual bronchodilation.

  • See what the IHS Markit Score report has to say about Innoviva Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Innoviva Inc.

    Short interest is moderate for INVA with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold INVA had net inflows of $3.08 billion over the last one-month.

  • Moving Average Crossover Alert: Innoviva (INVA)
    Zacks2 months ago

    Moving Average Crossover Alert: Innoviva (INVA)

    Innoviva, Inc. (INVA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

  • Business Wire2 months ago

    Once-daily Trelegy Ellipta gains expanded COPD indication in Europe

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), recognising its effect on exacerbations and making it the first single inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA). While bronchodilation is recognised as the foundation of COPD therapy, many patients may continue to struggle with symptoms and exacerbations over time.

  • GlobeNewswire2 months ago

    Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Investor's Business Daily2 months ago

    IBD 50 Stocks To Watch: This Stock Rallied Despite A Miss On Earnings And Revenue

    The stock market's reaction was interesting for a company that just missed on earnings and revenue.

  • Associated Press3 months ago

    Innoviva: 3Q Earnings Snapshot

    On a per-share basis, the Brisbane, California-based company said it had profit of 43 cents. The biopharmaceutical company posted revenue of $61.7 million in the period. Innoviva shares have dropped 1 ...

  • Business Wire3 months ago

    Innoviva Reports Third Quarter 2018 Financial Results

    BRISBANE, Calif.-- -- Total net revenue rose 26.8% to $61.7 million compared with the third quarter of 2017. Net income attributable to Innoviva stockholders increased 98.1% from the third quarter of 2017 to $47.1 million, or $0.43 per diluted share. The Company made a partial repayment of $110.0 million on its Term B loan. Innoviva, Inc. today reported financial results for the third quarter ended ...

  • See what the IHS Markit Score report has to say about Innoviva Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Innoviva Inc.

    Innoviva Inc NASDAQ/NGS:INVA

  • See what the IHS Markit Score report has to say about Innoviva Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Innoviva Inc.

    Short interest is moderate for INVA with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on October 1. Over the last one-month, outflows of investor capital in ETFs holding INVA totaled $203 million.

  • Business Wire4 months ago

    Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication in Europe

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/ vilanterol ‘FF/UMEC/VI’) in a broader group of patients with moderate to severe chronic obstructive pulmonary disease (COPD) and that labelling, if approved, will be updated to further reflect its effect on exacerbations of COPD. It would also reference the effect on exacerbations based on data from the InforMing the PAthway of COPD Treatment (IMPACT) study. Dr. Hal Barron, Chief Scientific Officer and President, R&D, GSK, said, “Many patients with COPD continue to experience exacerbations despite taking dual bronchodilator therapies.

  • See what the IHS Markit Score report has to say about Innoviva Inc.
    Markit4 months ago

    See what the IHS Markit Score report has to say about Innoviva Inc.

    Short interest is low for INVA with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on September 17. ETFs that hold INVA had net inflows of $2.84 billion over the last one-month.